# Comprehensive Table of Medically Important Bacteria

## GRAM-POSITIVE COCCI

| Type | Name | Test | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **GPC** | *Staphylococcus aureus* | Catalase +ve; Coagulase +ve; Beta-hemolysis on blood agar; Yellow colonies on nutrient agar | Nasal mucosa; Skin; Vagina (~30% general population) | Direct contact with infected person; Contact with contaminated objects/fomites; Inhaling infected droplets; Contaminated food | Exfoliative toxins A & B; Hemolysin; Alpha toxin; P-V leukocidins; TSST-1; Clumping factors; Coagulase; Enterotoxins | **Pyogenic:** Skin/soft tissue infections (folliculitis, abscess, necrotizing fasciitis); Cellulitis; Septicemia; Endocarditis; Osteomyelitis; Septic arthritis; Pneumonia; Post-surgical wound infection; Conjunctivitis. **Toxin-mediated:** Food poisoning; Toxic shock syndrome; Staphylococcal scalded skin syndrome | Hospitalization; Nursing home stay; Surgery, hemodialysis; Medical implants; IV/urinary catheters; Immunocompromised; IV drug use; Crowding; Tampon use; Chronic carriers | **Management:** MSSA: Cloxacillin, beta-lactams; MRSA: Vancomycin, daptomycin, linezolid; I&D of abscesses. **Prevention:** Good personal hygiene; Hand washing; Keep infections covered; Avoid sharing personal items; Food safety; Equipment disinfection |
| **GPC** | *Streptococcus pyogenes* (Group A Strep) | Catalase -ve; Beta-hemolysis; Bacitracin disc sensitive; Lancefield Group A antigen | Upper respiratory tract (3-5% adults, 10% children) | Droplet transmission | Capsular polysaccharide; M protein (antiphagocytic); Streptolysin O & S; Streptococcal pyrogenic exotoxins; Streptokinase; Hyaluronidase | **Pyogenic:** Pharyngitis; Tonsillitis; Skin/soft tissue infections (impetigo, erysipelas, necrotizing fasciitis). **Toxin-mediated:** Scarlet fever; Toxic shock syndrome. **Post-infectious sequelae:** Acute glomerulonephritis; Acute rheumatic fever | Immunologic disease occurs weeks after infection due to antibody cross-reaction with human tissues | **Management:** Penicillin G, oral penicillin V; Amoxicillin; Penicillin-allergy: Erythromycin, clindamycin, azithromycin. **Prevention:** Good hygiene; Hand washing; Prompt treatment of pharyngitis to prevent rheumatic fever |
| **GPC** | *Streptococcus pneumoniae* | Catalase -ve; Alpha-hemolysis; Optochin disc sensitive; Bile solubility +ve; Lancet-shaped diplococci; "Draughtman's colony" | Nasopharynx (5-10% adults, 20-40% children) | Respiratory droplets; Close contact; Aspiration of nasopharyngeal secretions | Capsular polysaccharides (antiphagocytic); Cell wall polysaccharides; Pneumolysin; PsaA (adherence); PspA, PspC (inhibit phagocytosis); Autolysin; Neuraminidase | Pneumonia; Meningitis; Otitis media; Sinusitis; Infective endocarditis; Pericarditis; Osteomyelitis; Septic arthritis | Depressed cough reflex; Alcohol/drug intoxication; Mucus accumulation; Bronchial obstruction; Prior viral infection; Pulmonary congestion/heart failure; Splenectomy; Sickle cell anemia; Head trauma | **Management:** Penicillin G, oral penicillin V; Ceftriaxone; Vancomycin; Levofloxacin; Penicillin-allergy: Erythromycin, clindamycin, azithromycin. **Prevention:** Vaccination |
| **GPC** | *Streptococcus agalactiae* (Group B Strep) | Catalase -ve; Small zone beta-hemolysis; Lancefield Group B antigen | Female genital tract (5-30%); Gastrointestinal tract | Vertical transmission during childbirth; Direct contact | Polysaccharide capsule (antiphagocytic) | **Neonates:** Neonatal meningitis; Neonatal sepsis. **Pregnant women:** UTI; Chorioamnionitis; Endometritis | Prolonged (>18 hrs) ruptured membranes; Premature delivery (<37 weeks); Maternal colonization | **Management:** Penicillin G, amoxicillin; May require combination with aminoglycosides. **Prevention:** Antibiotic prophylaxis to pregnant women (Penicillin G/ampicillin); Penicillin-allergy: Cefazolin, vancomycin; Screening of pregnant women (vaginal swab) |

## GRAM-POSITIVE BACILLI

| Type | Name | Test | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **GPR** | *Corynebacterium diphtheriae* | Club-shaped GPR; Non-spore forming; PCR for toxin genes | Skin; Upper respiratory tract; GI tract | Respiratory droplets; Direct contact with skin lesions | Diphtheria toxin (subunits A & B); Inhibits protein synthesis; Forms fibrinous exudate (pseudomembrane) | **Respiratory diphtheria:** Nasal, pharyngeal, tonsillar, laryngeal; Pseudomembrane formation; Fatal airway obstruction. **Cutaneous diphtheria:** Scaling rash/ulcers | Unimmunized individuals; Immunized can be asymptomatic carriers | **Management:** Anti-toxin (immediately on clinical diagnosis); Antibiotics (erythromycin/penicillin); Airway protection; Management of contacts. **Prevention:** Vaccination: DTaP (toxoid vaccine) |
| **GPR** | *Clostridium botulinum* | Anaerobic; Spore-forming; GPR | Soil & intestinal tract of humans/animals | Ingestion of preformed toxins; Ingestion of bacterial spores; Wound contamination with spores | Botulinum toxin; Protease inhibiting ACh release; Inhibits muscle stimulation causing flaccid paralysis | **Food botulism:** Nausea, vomiting, diarrhea; Flaccid paralysis. **Infant botulism:** Hypotonia (floppy baby); Weak cry; Feeding difficulty. **Wound botulism:** Muscle weakness & paralysis; Death from respiratory/cardiac failure | Ingestion of improperly canned food; Infants consuming honey; IV drug users with wound contamination | **Management:** Supportive care; Airway management. **Prevention:** Proper food handling; Adequate heating; Avoid honey in infants |
| **GPR** | *Clostridium tetani* | Anaerobic; Spore-forming; GPR; Endospores resistant to heat | Soil & intestinal tract of humans/animals | Spores enter through contaminated wounds | Tetanospasmin; Tetanolysin; Block release of inhibitory neurotransmitters; Sustained muscle contraction & spastic paralysis | Tetanus; Sustained muscle contraction; Spastic paralysis; Opisthotonus (arching of back); High mortality from respiratory failure | Skin puncture wounds; Foreign body in wounds; Unimmunized individuals | **Management:** Passive immunization (human tetanus immunoglobulin); Toxoid vaccines; Supportive care. **Prevention:** Anti-tetanus toxoid vaccination |
| **GPR** | *Clostridium perfringens* | Anaerobic; Spore-forming; GPR | Soil & intestinal tract of humans/animals | Spores contaminating wounds or food | Alpha toxin (lecithinase); Hemolytic toxin; Degrades tissues/cell membranes; Causes thrombosis & tissue ischemia; Enterotoxin (food poisoning); Other: Hyaluronidase, collagenase, DNase | **Gas gangrene/myonecrosis:** Necrotizing wound infection; Gas production in tissues; Rapid progression; Rapidly fatal if untreated. **Food poisoning:** Watery diarrhea; Severe hemorrhagic diarrhea | Wound contamination; Improperly stored food contaminated with spores | **Management:** Antibiotic therapy (metronidazole); Prompt surgical debridement; Wound care; Supportive care. **Prevention:** Proper food handling; Adequate heating; Hygiene |
| **GPR** | *Clostridium difficile* | Anaerobic; Spore-forming; GPR; Spores resistant to alcohol | GI tract (3% healthy adults, 8-10% hospitalized patients) | Endospores transmitted person-to-person via fecal-oral route | Enterotoxin A (alters fluid secretion); Enterotoxin B (disrupts cytoskeleton); Spores resistant to alcohol & stomach acidity | Antibiotic-associated diarrhea; Antibiotic-induced colitis; Pseudomembranous colitis; Watery diarrhea; Abdominal pain | Antibiotic use (clindamycin, ampicillin, amoxicillin, cephalosporins, fluoroquinolones); Elimination of normal gut flora; Hospitalization | **Management:** Discontinue offending antibiotic; Specific antibiotic therapy. **Prevention:** Avoid inappropriate antibiotic prescription; Hand washing with soap & water (NOT alcohol); Equipment/environment disinfection |

## GRAM-NEGATIVE BACTERIA - ENTEROBACTERIACEAE

| Type | Name | Test | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **GNR** | *Escherichia coli* | Straight GNR; Facultative anaerobe; Lactose-fermenting (pink on MacConkey); Oxidase -ve; Indole +ve; Motile | Colon; Rectum; Vagina; Outer urethra | Ingestion of contaminated food (foodborne); Person-to-person contact; Contact with animals; Contact with fomites contaminated with fecal material | **Diarrhoeagenic strains:** ETEC: enterotoxins; EHEC/STEC/VTEC: Shiga toxin; EPEC: attaching & effacing; EIEC: invasion; EAEC: aggregative adherence | **Diarrhoeagenic:** ETEC: Traveler's diarrhea (watery); EHEC: Hemorrhagic colitis (bloody), HUS; EPEC: Infantile diarrhea (watery); EIEC: Dysentery (bloody); EAEC: Persistent watery diarrhea. **Other infections:** UTI; Neonatal meningitis; Hospital-acquired pneumonia; Bacteremia; Wound infection | Contaminated food/water consumption; Hospitalization; Neonates; Immunocompromised | **Management:** Supportive care for gastroenteritis; Antibiotics for invasive infections. **Prevention:** ETEC: Prudent food/drink selection when traveling; EHEC: Properly cooked food; Standard & contact precautions for MDR strains; Hand hygiene |
| **GNR** | *Klebsiella pneumoniae* | Straight GNR; Facultative anaerobe; Lactose-fermenting (pink, wet/mucoid on MacConkey); Oxidase -ve; Indole -ve; Nonmotile | Colon; Rectum; Vagina; Outer urethra | Person-to-person contact/transmission (especially in hospitals) | Capsule (antiphagocytic); Fimbriae (adherence) | Pneumonia (primarily hospital-acquired); UTI; Bacteremia/bloodstream infection | Hospitalization; Impaired host immune defenses (diabetes, cancer) | **Management:** Appropriate antibiotics. **Prevention:** Standard & contact precautions for MDR strains |
| **GNR** | *Proteus* species | Straight GNR; Facultative anaerobe; Nonlactose-fermenting (colorless on MacConkey); Oxidase -ve; Urease +ve; Motile; Swarming motility on blood agar; *P. mirabilis*: Indole -ve; *P. vulgaris*: Indole +ve | Colon; Rectum; Vagina; Outer urethra; Also widespread in environment | Person-to-person through direct/indirect contact; Via fomites; Contaminated catheters (especially urinary) | Urease production; Swarming motility; Fimbriae | UTI (most common); Wound infections; Bacteremia; Hospital-acquired pneumonia | Normal flora causing infection after leaving GI tract; Catheterization; Hospitalization | **Management:** Appropriate antibiotics. **Prevention:** Standard & contact precautions for MDR strains; Proper catheter care |
| **GNR** | *Salmonella* species | Straight GNR; Facultative anaerobes; Nonlactose-fermenting (colorless on MacConkey); Oxidase -ve; Mainly motile | N/A (zoonotic) | Consumption of contaminated food sources (beef, poultry, eggs); Contaminated food/water; Contact with acutely infected individual/chronic carrier | **Nontyphoidal:** Enterotoxin; Invasion of intestinal mucosa. **Typhoidal:** Invasion & intracellular survival; Vi antigen (capsule) | **Nontyphoidal (*S. Enteritidis*, *S. Typhimurium*):** Food-poisoning gastroenteritis; Nausea, vomiting, fever, diarrhea, cramping. **Typhoidal (*S. Typhi*, *S. Paratyphi*):** Enteric fever (typhoid/paratyphoid); Severe systemic illness; Fever, abdominal pain; Rose spots; Hepatosplenomegaly; Chronic carriage | **Nontyphoidal:** Healthy individuals mostly; Impaired cellular immunity increases risk. **Typhoidal:** Consumption contaminated food/water; Contact with carrier | **Management:** Supportive care; Antibiotics for severe/invasive disease. **Prevention:** Nontyphoidal: Hand hygiene, food safety, proper cooking; Typhoidal: Behavioral precautions in endemic areas, vaccination |

## GRAM-NEGATIVE BACTERIA - NONENTEROBACTERIACEAE (CURVED GNR)

| Type | Name | Test | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Curved GNR** | *Vibrio cholerae* | Curved, comma-shaped GNR; Facultative anaerobe; Late/slow lactose-fermenter; Oxidase +ve; Yellow colonies on TCBS (sucrose-fermenting) | N/A (free-living in aquatic/marine environments) | Consumption of contaminated water/food | Cholera toxin (enterotoxin); TCP (toxin co-regulated pilus); Mucinase | Cholera (gastroenteritis); "Rice water" stool; Most infections asymptomatic; Can cause massive watery diarrhea; Severe dehydration; High morbidity/mortality if severe | Consumption of contaminated water; Poor sanitation; Endemic regions | **Management:** Rehydration therapy; Antibiotics in severe cases. **Prevention:** Clean water supply; Appropriate sanitation; Travelers: Avoid tap water, raw/undercooked seafood, street food |
| **Curved GNR** | *Vibrio parahaemolyticus* | Curved GNR; Facultative anaerobe; Oxidase +ve; Green colonies on TCBS (nonsucrose-fermenting) | N/A (free-living in marine environments) | Consumption of contaminated seafood; Marine recreational activities (swimming) | Thermostable direct hemolysin; Type III secretion systems | Gastroenteritis (diarrhea, abdominal cramps, nausea, vomiting, fever); Wound infections | Consumption of contaminated seafood; Marine recreational water exposure | **Management:** Supportive care; Antibiotics for severe cases. **Prevention:** Avoid cross-contamination; Proper seafood handling; Avoid poorly maintained pools |

## GRAM-NEGATIVE COCCI

| Type | Name | Test | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **GNC** | *Neisseria meningitidis* | GN "coffee-bean/kidney-bean" diplococci; Oxidase +ve; Nonmotile; Grows on chocolate agar | Can colonize throat; Nasopharyngeal carriage | Person-to-person through respiratory droplets (≥5 microns); Colonization prerequisite for systemic infection | Capsular polysaccharide; Pili (adherence); Endotoxin (LPS); IgA protease; Iron acquisition systems | Meningococcal meningitis; Meningococcemia; Septicemia; Characteristic petechial/purpuric rash | Age groups: <5 years, 16-21 years, ≥65 years; Nasopharyngeal carriage; Complement deficiency; University students; Intimate kissing with multiple partners; Occupational exposure (lab workers) | **Management:** Urgent antibiotic therapy; Supportive care. **Prevention:** Vaccination (for risk groups); Droplet precautions for 24 hrs after effective antibiotics; Antimicrobial chemoprophylaxis for close contacts |
| **GNC** | *Neisseria gonorrhoeae* | GN "coffee-bean/kidney-bean" diplococci; Oxidase +ve; Nonmotile; Grows on chocolate agar | N/A (always pathogenic when identified) | Sexual contact; Vertical transmission during childbirth | Pili (adherence, antigenic variation); Opa proteins; Por proteins; LOS (endotoxin); IgA protease | Gonorrhea (purulent STI); **Women:** Cervicitis (vaginal pruritus, mucopurulent discharge); **Men:** Urethritis (penile discharge, dysuria); Neonatal conjunctivitis (ophthalmia neonatorum) | Young age (adolescents/young adults); Recent new/multiple sexual partners; Previous gonorrhea | **Management:** Antibiotics (ceftriaxone-based regimens). **Prevention:** Barrier methods (condoms); Partner notification & treatment |

## GRAM-NEGATIVE BACTERIA - NONENTEROBACTERIACEAE (STRAIGHT GNR)

| Type | Name | Test | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **GNR** | *Pseudomonas aeruginosa* | Straight GNR; Obligate aerobe; Oxidase +ve; Motile; Blue-green colonies on nutrient agar; Produces pyocyanin & pyoverdin pigments | Environment (soil, water, faucets, sinks, respiratory equipment, contact lens solutions) | In hospitals: Direct contact via healthcare workers' hands; Indirect contact via contaminated equipment; Recreational waters | Exotoxin A; Exoenzyme S; Elastase; Alkaline protease; Pyocyanin; Biofilm formation | Pneumonia; Lung abscesses; Bacteremia; UTI; Skin infections (folliculitis "hot tub rash", ecthyma gangrenosum, burn wounds); Otitis media/externa ("swimmer's ear"); Eye infections | Hospitalized patients; Immunocompromised; Surgical wounds; Skin burns; Ventilators; Central lines/urinary catheters; Recreational water exposure | **Management:** Antibiotics (antipseudomonal agents). **Prevention:** Standard & contact precautions for MDR strains; Avoid poorly maintained pools; Proper contact lens care |
| **GNR** | *Burkholderia pseudomallei* | Straight GNR with bipolar staining ("safety pins"); Oxidase +ve; Wrinkled "cornflower" colonies on blood agar; "Metallic sheen" on MacConkey | Environment (mud/soil, fresh surface water in endemic regions) | Percutaneous inoculation during contact with contaminated soil/water; Inhalation of contaminated dust/water droplets; Ingestion of contaminated water (uncommon) | Capsule; Type III & VI secretion systems; Flagella; Quorum sensing systems | Melioidosis (Whitmore's disease); Most asymptomatic; Pneumonia (most common when symptomatic); Localized skin infection; Can be fatal | Diabetes; Alcoholism; Chronic renal disease; High-risk occupations (farming) | **Management:** Appropriate antibiotics (ceftazidime, meropenem); Prolonged therapy. **Prevention:** Cover wounds with waterproof dressings; Wear boots/gloves in endemic areas; Avoid exposure to soil/water if debilitating disease; Thorough wound cleansing |

## GRAM-NEGATIVE COCCOBACILLI

| Type | Name | Test | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **GNCB** | *Brucella* species | Small GN coccobacilli; Most strains oxidase +ve; Urease +ve; Nonmotile | N/A (zoonotic) | Consumption of food products from infected animals (unpasteurized milk/dairy); Direct contact with blood/fluids/secretions of infected animals through skin cuts/conjunctiva; Inhalation of contaminated aerosols | Intracellular survival; LPS (reduced endotoxicity); Inhibition of phagosome-lysosome fusion | Brucellosis; Prolonged fever (≥2 weeks); Nonspecific symptoms; Can cause focal infections (epidural abscess, spondylitis) | High-risk occupations (farmers, slaughterhouse workers, vets, microbiologists); Consumption of unpasteurized dairy | **Management:** Prolonged antibiotic therapy (combination). **Prevention:** Public education; Consume only pasteurized dairy; Thoroughly cooked meat; PPE for high-risk occupations |

## PLEOMORPHIC GRAM-NEGATIVE BACTERIA

| Type | Name | Test | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Pleomorphic GNR** | *Acinetobacter baumannii* | Pleomorphic on Gram stain (GNR, GNC, or GNCB); Nonlactose-fermenter; Oxidase -ve; Nonmotile | Environment (water, soil); Hospitals (ventilation equipment, catheters); Human skin, wounds, respiratory & GI tracts | Direct contact (person-to-person via healthcare workers); Contact with contaminated surfaces/fomites | Biofilm formation; Resistance to desiccation; Outer membrane proteins; Efflux pumps | Healthcare-associated infections: Pneumonia (esp. ventilator-associated); Bacteremia; UTI; Wound infections; Meningitis | Hospitalization (esp. ICU); Surgery; Catheterization; Antibiotic exposure | **Management:** Antibiotics (often MDR, may require carbapenems/colistin). **Prevention:** Regular environmental cleaning; Standard & contact precautions for MDR strains |

## SPIROCHAETES

| Type | Name | Test | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Spirochaete** | *Leptospira interrogans* | Spiral-shaped; Not visible on Gram stain; Seen on darkfield microscopy | N/A (zoonotic - rodents, cattle, sheep, goats) | Exposure to environmental sources (urine from infected animals, water/soil contaminated with animal urine, infected animal tissue); Entry via cuts/abraded skin, mucous membranes, conjunctivae | Outer membrane proteins; Adhesins; Hemolysins; Lipopolysaccharide | Leptospirosis; Asymptomatic/subclinical; Self-limited systemic infection; Severe multiorgan failure; Symptoms: Abrupt fever, rigors, myalgias, headache; Conjunctival suffusion (characteristic) | High-risk occupations (farmers, sewer workers, vets); Outdoor recreational activities (jungle trekking, swimming, kayaking) in endemic areas; Tropical/temperate climates | **Management:** Antibiotics (penicillin, doxycycline); Supportive care. **Prevention:** Eliminate contact with infected animals; Avoid swimming in potentially contaminated water; Protective clothing/footwear for at-risk occupations |

---

## ADDITIONAL MEDICALLY IMPORTANT BACTERIA (Brief Overview)

| Type | Name | Major Clinical Infections |
|------|------|---------------------------|
| **GNR** | *Enterobacter* species | Nosocomial: UTI, pneumonia |
| **GNR** | *Serratia marcescens* | Nosocomial: Ventilator-associated pneumonia, burn/surgical wounds, device-related infections, post-neurosurgical meningitis |
| **GNR** | *Citrobacter* species | Nosocomial: Bacteremia, UTI, wound infection |
| **GNR** | *Shigella* species | Gastroenteritis (watery diarrhea, dysentery) |
| **GNR** | *Yersinia* species | Gastroenteritis (*Y. enterocolitica*), plague (*Y. pestis*) |
| **GNR** | *Bacteroides fragilis* | Abscess (intra-abdominal, brain, lung) - obligate anaerobe |
| **GNR** | *Campylobacter jejuni* | Gastroenteritis |
| **GNCB** | *Haemophilus influenzae* | Sinusitis, acute otitis media, conjunctivitis, community-acquired pneumonia |
| **GNCB** | *Moraxella catarrhalis* | Sinusitis, acute otitis media |
| **GNCB** | *Bordetella pertussis* | Pertussis (whooping cough) |
| **GNCB** | *Francisella tularensis* | Tularemia |
| **GNCB** | *Pasteurella multocida* | Skin/soft tissue infections (cellulitis), bone/joint infections, respiratory infections, bacteremia |
| **Spirochaete** | *Treponema pallidum* | Syphilis |
| **Spirochaete** | *Borrelia burgdorferi* | Lyme disease |
| **Cannot be Gram stained** | *Chlamydia* species | Community-acquired pneumonia (*C. pneumoniae*), psittacosis (*C. psittaci*), urethritis/trachoma (*C. trachomatis*) |
| **Cannot be Gram stained** | *Mycoplasma pneumoniae* | Community-acquired pneumonia |
| **Cannot be Gram stained** | *Legionella pneumophila* | Community-acquired pneumonia (Legionnaires' disease) |
| **Cannot be Gram stained** | *Rickettsia prowazekii* | Epidemic typhus (zoonotic) |
| **Cannot be Gram stained** | *Orientia tsutsugamushi* | Scrub typhus (zoonotic) |
| **Cannot be Gram stained** | *Coxiella burnetii* | Q fever (zoonotic) |

---

**Abbreviations:**
- GPC = Gram-positive cocci
- GPR = Gram-positive rods/bacilli
- GNC = Gram-negative cocci
- GNR/GNB = Gram-negative rods/bacilli
- GNCB = Gram-negative coccobacilli
- UTI = Urinary tract infection
- MDR = Multidrug-resistant
- STI = Sexually transmitted infection
- PPE = Personal protective equipment
- I&D = Incision and drainage
- ICU = Intensive care unit
- HUS = Hemolytic uremic syndrome
- ACh = Acetylcholine
- LPS = Lipopolysaccharide
- PCR = Polymerase chain reaction


# Comprehensive Table of Medically Important Microorganisms

## MEDICALLY IMPORTANT FUNGI

### SUPERFICIAL MYCOSES

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Superficial** | *Malassezia furfur* | KOH preparation showing "spaghetti and meatballs" appearance; Culture on SDA with olive oil overlay | Skin (part of normal flora) | Direct contact; Endogenous | Lipase; Phospholipase; Inhibits melanin synthesis | Pityriasis versicolor (tinea versicolor); Hypopigmented skin lesions; Itching; Intense scaling; Seborrheic dermatitis; Dandruff | Hot, humid climate; Oily skin; Immunosuppression | **Management:** Azole creams; Selenium sulfide; Ketoconazole topical; Oral ketoconazole/itraconazole. **Prevention:** Good hygiene; Keep skin dry |
| **Superficial** | *Exophiala werneckii* | Dematiaceous fungus; Brown colonies on SDA | Skin (stratum corneum) | Direct contact; Environmental (soil, wood) | Melanin production | Tinea nigra (tinea nigra palmaris); Dark brown to black discoloration on palm; Asymptomatic | Tropical/subtropical regions; Direct contact with contaminated surfaces | **Management:** Topical azoles; Keratolytic agents. **Prevention:** Good hygiene |
| **Superficial** | *Trichosporon beigelii* | Hyphae and arthroconidia on microscopy | Hair shaft | Direct contact | Adherence to hair shaft | White piedra; Soft, yellowish nodules on hair (axillary, pubic, beard, scalp) | Tropical regions; Poor hygiene | **Management:** Shaving affected hair; Topical azoles. **Prevention:** Good hygiene |
| **Superficial** | *Piedraia hortae* | Dematiaceous fungus; Ascospores in nodules | Hair shaft | Direct contact | Adherence to hair shaft | Black piedra; Hard, dark nodules on hair shaft | Tropical underdeveloped countries; Poor hygiene | **Management:** Shaving affected hair; Topical azoles. **Prevention:** Good hygiene |

### CUTANEOUS MYCOSES (DERMATOPHYTOSES)

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Cutaneous** | *Microsporum* species (*M. canis*, *M. gypseum*) | Spindle-shaped macroconidia; Bright golden yellow reverse on SDA; Wood's lamp fluorescence (silvery) | Not part of normal flora | Anthropophilic (human); Zoophilic (dogs, cats); Geophilic (soil) | Keratinase; Protease; Ectothrix invasion (arthroconidia outside hair shaft) | Tinea capitis (head); Tinea corporis (body); Raised, red, circular lesions (ringworm) | Contact with infected animals/humans; Abrasion/laceration of skin | **Management:** Topical/oral azoles; Terbinafine; Griseofulvin. **Prevention:** Avoid contact with infected animals; Good hygiene; Keep skin dry |
| **Cutaneous** | *Trichophyton* species (*T. rubrum*, *T. tonsurans*) | Pencil-shaped macroconidia; Culture on SDA | Not part of normal flora | Anthropophilic; Zoophilic (cattle, horses); Geophilic | Keratinase; Protease; Endothrix invasion (arthroconidia inside hair); Ectothrix invasion | Tinea pedis (athlete's foot); Tinea unguium (onychomycosis); Tinea cruris (jock itch); Tinea barbae; Tinea capitis; Tinea corporis | Occlusive footwear; Communal bathing; Contact with infected individuals; Immunosuppression | **Management:** Topical/oral azoles; Terbinafine; Griseofulvin. **Prevention:** Keep feet dry; Avoid sharing towels/shoes; Good hygiene |
| **Cutaneous** | *Epidermophyton floccosum* | Club-shaped macroconidia; No microconidia | Not part of normal flora | Anthropophilic | Keratinase; Protease | Tinea cruris; Tinea pedis; Tinea corporis; Does NOT infect hair | Warm, moist environments; Occlusive clothing | **Management:** Topical/oral azoles; Terbinafine. **Prevention:** Keep skin dry; Avoid tight clothing |
| **Cutaneous** | *Candida albicans* and other *Candida* spp. | Germ tube test +ve (*C. albicans*); Pseudohyphae on microscopy; Gram +ve budding yeast | Skin, mucous membranes, GI tract, vagina (normal flora) | Endogenous; Direct contact | Adherence (adhesins); Hyphal formation; Biofilm formation; Secreted enzymes (proteinases, phospholipases); Candidalysin toxin | Candidiasis of skin, mucosa, nails; Oral thrush; Vaginal candidiasis; Diaper rash; Intertrigo | Immunosuppression; Diabetes; Antibiotic use; Steroid therapy; Pregnancy; Tight clothing; Moisture | **Management:** Topical/oral azoles; Nystatin. **Prevention:** Good hygiene; Keep skin dry; Control diabetes |

### SUBCUTANEOUS MYCOSES

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Subcutaneous** | *Sporothrix schenckii* | Thermal dimorphism: Yeast at 37°C (cigar-shaped); Mold at 25°C with "flower" arrangement of conidia | Environment (soil, plants) | Traumatic inoculation (thorns, wood splinters) | Thermal dimorphism; Melanin production; Adhesins | Sporotrichosis; Multiple nodular lesions along lymphatic channels; Ulceration of subcutaneous tissue; Lymphocutaneous pattern | Agricultural workers; Forest rangers; Horticulturists; Florists; Farming/gardening | **Management:** Itraconazole; Amphotericin B; Potassium iodide. **Prevention:** Protective clothing; Minimize accidental inoculation |
| **Subcutaneous** | *Fonsecaea pedrosoi*, *Cladosporium carrionii*, *Phialophora verrucosa* | Dematiaceous fungi; Muriform/sclerotic bodies in tissue (brown, 4-12 μm) | Environment (soil, decaying vegetation) | Traumatic inoculation | Melanin production; Granuloma formation | Chromoblastomycosis; Slow-growing verrucous lesions; Hyperplasia of epidermal tissue; Commonly on lower extremities | Barefoot agricultural workers; Tropical regions | **Management:** Surgical excision; Itraconazole; Terbinafine; Amphotericin B. **Prevention:** Protective footwear; Avoid barefoot walking |
| **Subcutaneous** | *Madurella mycetomatis*, *Pseudallescheria boydii*, *Exophiala jeanselmei* | Granules in tissue (white, brown, black); Splendore-Hoeppli reaction | Environment (soil) | Traumatic inoculation | Granule formation; Chronic inflammation | Mycetoma (Madura foot); Local swelling; Multiple abscesses; Draining sinuses producing granules | Barefoot individuals; Impoverished populations; Agricultural workers; Tropical regions (India, Africa, Latin America) | **Management:** Surgical debridement; Antifungals (varies by organism). **Prevention:** Protective footwear; Wound care |

### ENDEMIC/SYSTEMIC MYCOSES

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Endemic** | *Blastomyces dermatitidis* | Thermal dimorphism: Broad-based budding yeast at 37°C; Mold at 25°C; GMS/PAS staining | Environment (soil) in endemic areas | Inhalation of conidia | Thermal dimorphism; BAD1 adhesin; Inhibition of TNF-α | Blastomycosis; Pulmonary infection; Cutaneous lesions; Bone/joint involvement; CNS involvement; Fever, cough, night sweats, weight loss | Endemic regions (Mississippi, Ohio River basins); Outdoor activities; Immunosuppression | **Management:** Amphotericin B; Itraconazole. **Prevention:** Avoid high-risk areas during outbreaks |
| **Endemic** | *Coccidioides immitis/posadasii* | Spherules with endospores in tissue; Arthroconidia in culture (BSL-3); Yellow colonies on TCBS | Alkaline soil in semiarid regions | Inhalation of arthroconidia | Spherule formation (resists phagocytosis); Endospore production | Coccidioidomycosis (Valley fever); Pneumonia; Meningitis; Osteomyelitis; Skin granulomas; Flu-like illness | Endemic areas (SW USA, California, Arizona); Dust storms; Immunocompromised; Pregnancy; ≥60 years | **Management:** Fluconazole; Amphotericin B for severe cases. **Prevention:** Avoid dust in endemic areas; Mask during dust storms |
| **Endemic** | *Histoplasma capsulatum* | Thermal dimorphism: Small budding yeast (2-4 μm) inside macrophages at 37°C; Tuberculate macroconidia at 25°C (BSL-3) | Soil contaminated with bat/bird droppings | Inhalation of microconidia | Thermal dimorphism; Intracellular survival in macrophages; Calcium-binding protein | Histoplasmosis (Ohio Valley fever); Pulmonary granulomas; Disseminated disease; Hepatosplenomegaly | Endemic areas (Ohio, Mississippi valleys); Cave exploration; Cleaning bird roosts; Immunocompromised | **Management:** Itraconazole; Amphotericin B for severe cases. **Prevention:** Avoid high-risk environments; Respiratory protection |
| **Endemic** | *Paracoccidioides brasiliensis* | Thermal dimorphism: Multiple budding yeast ("pilot's wheel") at 37°C; Mold at 25°C | Soil (armadillo burrows) | Inhalation of conidia | Thermal dimorphism; Gp43 adhesin; Estrogen-binding protein (males more susceptible) | Paracoccidioidomycosis; Pulmonary lesions; Oral/throat lesions; Lymphadenopathy; Hepatosplenomegaly; Weight loss | Endemic areas (Central/South America, Brazil); Male gender; Rural areas; Agricultural workers | **Management:** Itraconazole; Amphotericin B. **Prevention:** Avoid high-risk environments |
| **Endemic** | *Talaromyces (Penicillium) marneffei* | Thermal dimorphism: Yeast with central septation at 37°C; Mold with red pigment at 25°C | Environment; Bamboo rats (reservoir) | Inhalation | Thermal dimorphism; Intracellular survival | Disseminated infection in HIV patients; Fever, anemia, weight loss; Skin lesions; Hepatosplenomegaly | Southeast Asia (Indochina); HIV/AIDS; Immunosuppression | **Management:** Amphotericin B followed by itraconazole. **Prevention:** Avoid exposure to bamboo rats; HAART for HIV patients |

### OPPORTUNISTIC MYCOSES

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Opportunistic** | *Candida albicans* | Germ tube test +ve; Pseudohyphae in tissue; Gram +ve budding yeast; Pink colonies on SDA | Skin, oral cavity, GI tract, vagina (40-80% healthy individuals) | Endogenous overgrowth; Direct contact | Adherence; Hyphal formation (reverse dimorphism); Biofilm; Proteinases; Phospholipases; Candidalysin | Oral thrush (pseudomembranous candidiasis); Vaginal candidiasis; Esophagitis; Candidemia; Disseminated candidiasis; Endocarditis; Endophthalmitis | Immunosuppression; HIV/AIDS; Diabetes; Antibiotic use; Steroid therapy; Indwelling catheters; Prolonged hospitalization; Cancer; Transplantation | **Management:** Fluconazole; Echinocandins (caspofungin); Amphotericin B; Remove catheters. **Prevention:** HAART for HIV; Control diabetes; Minimize antibiotic use; Catheter care |
| **Opportunistic** | *Candida auris* | Germ tube -ve; Identification requires MALDI-TOF/PCR; Cream colonies on SDA | Skin, healthcare environment | Healthcare-associated transmission; Contaminated surfaces | Biofilm formation; Multidrug resistance; Environmental persistence | Candidemia; Wound infections; Ear infections; Healthcare-associated outbreaks | Hospitalization; ICU admission; Indwelling devices; Recent surgery; Diabetes; Immunosuppression | **Management:** Echinocandins (often resistant to azoles); Amphotericin B. **Prevention:** Strict infection control; Environmental cleaning; Contact precautions; Screening |
| **Opportunistic** | *Cryptococcus neoformans/gattii* | India ink showing capsule (halo); Urease +ve; Brown colonies on Niger seed agar; Cryptococcal antigen test | Environment (soil, bird droppings, eucalyptus trees) | Inhalation of basidiospores | Polysaccharide capsule (antiphagocytic); Melanin production; Urease; Phospholipase | Cryptococcal meningitis/meningoencephalitis; Pulmonary cryptococcosis; Cutaneous lesions; Budding yeast with wide capsule in CSF | HIV/AIDS (CD4 <100); Organ transplantation; Corticosteroid therapy; Malignancy; *C. gattii* can infect immunocompetent | **Management:** Amphotericin B + flucytosine (induction); Fluconazole (consolidation/maintenance). **Prevention:** HAART for HIV; Cryptococcal antigen screening; Fluconazole prophylaxis |
| **Opportunistic** | *Aspergillus* species (*A. fumigatus*, *A. flavus*, *A. niger*) | Hyaline septate hyphae with dichotomous branching (45° acute angle); Conidial heads with phialides; Galactomannan antigen | Ubiquitous in environment (soil, decaying vegetation) | Inhalation of conidia | Thermotolerance; Protease; Elastase; Gliotoxin; Angioinvasion | Allergic bronchopulmonary aspergillosis (ABPA); Aspergilloma (fungus ball); Invasive pulmonary aspergillosis; Disseminated aspergillosis; Sinusitis | Neutropenia; Leukemia; Lymphoma; Bone marrow transplant; Corticosteroid use; Chronic lung disease (TB, sarcoidosis); Immunosuppression | **Management:** Voriconazole; Amphotericin B; Caspofungin; Surgical resection. **Prevention:** HEPA filtration in high-risk areas; Antifungal prophylaxis; Minimize dust exposure during construction |
| **Opportunistic** | *Mucor*, *Rhizopus*, *Absidia* | Broad, irregular, non-septate hyphae; Branching at right angles; Sporangiophores with sporangia | Ubiquitous in environment (soil, decaying organic matter) | Inhalation of sporangiospores; Direct inoculation | Ketone reductase (thrives in acidic, high glucose); Angioinvasion; Thrombosis | Rhinocerebral mucormycosis; Pulmonary mucormycosis; Cutaneous mucormycosis; Disseminated disease; Necrosis, ischemia, infarction | Diabetes mellitus (especially DKA); Leukemia; Lymphoma; Corticosteroid treatment; Deferoxamine therapy; Burns; Trauma | **Management:** Liposomal amphotericin B; Posaconazole; Surgical debridement; Control diabetes. **Prevention:** Control diabetes; Avoid corticosteroid overuse |
| **Opportunistic** | *Pneumocystis jirovecii* | GMS/Toluidine blue staining showing cysts; DFA; PCR | Lung (asymptomatic carriage possible) | Inhalation; Person-to-person | Attachment to type I pneumocytes; Alveolar inflammation | Pneumocystis pneumonia (PCP); Dyspnea; Dry cough; Fever; Hypoxemia; Bilateral interstitial infiltrates | HIV/AIDS (CD4 <200); Organ transplantation; Corticosteroid therapy; Immunosuppression | **Management:** Trimethoprim-sulfamethoxazole (TMP-SMX); Pentamidine; Steroids for severe cases. **Prevention:** TMP-SMX prophylaxis when CD4 <200; HAART for HIV |

---

## MEDICALLY IMPORTANT VIRUSES (SELECTED)

### DNA VIRUSES

| Family | Virus | Genome | Envelope | Transmission | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|--------|-------|--------|----------|--------------|------------------------|-------------|----------------------------------|
| **Herpesviridae** | Herpes Simplex Virus 1 (HSV-1) | dsDNA, linear | Enveloped | Direct contact; Saliva; Lesion secretions | Cold sores; Oral herpes; Keratitis; Encephalitis; Neonatal herpes | Close contact; Immunosuppression | **Management:** Acyclovir, valacyclovir. **Prevention:** Avoid contact during outbreaks |
| **Herpesviridae** | Herpes Simplex Virus 2 (HSV-2) | dsDNA, linear | Enveloped | Sexual contact; Vertical transmission | Genital herpes; Neonatal herpes; Meningitis | Multiple sexual partners; Unprotected sex | **Management:** Acyclovir, valacyclovir. **Prevention:** Safe sex practices; Cesarean delivery if active lesions |
| **Herpesviridae** | Varicella-Zoster Virus (VZV) | dsDNA, linear | Enveloped | Respiratory droplets; Direct contact | Chickenpox (varicella); Shingles (herpes zoster); Post-herpetic neuralgia | Childhood (chickenpox); Age >50, immunosuppression (zoster) | **Management:** Acyclovir, valacyclovir. **Prevention:** Varicella vaccine; Zoster vaccine |
| **Herpesviridae** | Cytomegalovirus (CMV) | dsDNA, linear | Enveloped | Saliva; Sexual contact; Blood transfusion; Vertical transmission; Transplantation | Mononucleosis-like syndrome; Congenital CMV (hearing loss, developmental delay); CMV retinitis; Pneumonitis | Immunosuppression; HIV/AIDS; Transplantation; Pregnancy | **Management:** Ganciclovir, valganciclovir. **Prevention:** Screening blood/organs; HAART for HIV |
| **Herpesviridae** | Epstein-Barr Virus (EBV) | dsDNA, linear | Enveloped | Saliva | Infectious mononucleosis; Nasopharyngeal carcinoma; Burkitt's lymphoma; Hodgkin's lymphoma | Adolescents/young adults; Endemic areas (NPC, Burkitt's) | **Management:** Supportive care. **Prevention:** Avoid sharing saliva |
| **Herpesviridae** | Human Herpesvirus 8 (HHV-8) | dsDNA, linear | Enveloped | Sexual contact; Saliva; Vertical transmission | Kaposi's sarcoma; Primary effusion lymphoma; Multicentric Castleman disease | HIV/AIDS; Immunosuppression | **Management:** HAART; Chemotherapy. **Prevention:** HAART for HIV |
| **Adenoviridae** | Adenovirus | dsDNA, linear | Non-enveloped | Respiratory droplets; Fecal-oral; Fomites | Pharyngitis; Conjunctivitis (pink eye); Gastroenteritis; Pneumonia; Hemorrhagic cystitis | Crowding; Daycare; Military recruits; Immunosuppression | **Management:** Supportive care. **Prevention:** Hand hygiene; Avoid sharing towels |
| **Papillomaviridae** | Human Papillomavirus (HPV) | dsDNA, circular | Non-enveloped | Sexual contact; Skin contact | Genital warts (HPV 6, 11); Cervical cancer (HPV 16, 18); Oropharyngeal cancer; Skin warts | Multiple sexual partners; Unprotected sex; Immunosuppression | **Management:** Cryotherapy; Surgical removal. **Prevention:** HPV vaccine; Safe sex; Pap smear screening |
| **Polyomaviridae** | BK Virus | dsDNA, circular | Non-enveloped | Unknown (asymptomatic in healthy) | BK virus nephropathy; Hemorrhagic cystitis | Kidney transplantation; Bone marrow transplantation; Immunosuppression | **Management:** Reduce immunosuppression. **Prevention:** Monitoring in transplant patients |
| **Polyomaviridae** | JC Virus | dsDNA, circular | Non-enveloped | Unknown (asymptomatic in healthy) | Progressive multifocal leukoencephalopathy (PML) | HIV/AIDS; Immunosuppression; Certain biologics (natalizumab) | **Management:** HAART; Discontinue causative agent. **Prevention:** HAART for HIV; Monitor in high-risk patients |
| **Poxviridae** | Variola virus | dsDNA, linear | Enveloped (complex) | Respiratory droplets; Direct contact | Smallpox (eradicated 1980) | N/A (eradicated) | **Management:** N/A. **Prevention:** Vaccination (no longer routine) |
| **Poxviridae** | Vaccinia virus | dsDNA, linear | Enveloped (complex) | Laboratory exposure; Bioterrorism concern | Localized pustular lesions; Used in smallpox vaccine | Laboratory workers; Military personnel | **Management:** Supportive care. **Prevention:** Proper handling; Vaccination if indicated |
| **Poxviridae** | Molluscum contagiosum virus | dsDNA, linear | Enveloped (complex) | Direct contact; Fomites; Sexual contact | Molluscum contagiosum (umbilicated papules) | Children; Immunosuppression; Sexual contact | **Management:** Cryotherapy; Curettage; Self-limited. **Prevention:** Avoid sharing towels; Safe sex |
| **Hepadnaviridae** | Hepatitis B Virus (HBV) | dsDNA (circular, partial ds) with RT | Enveloped | Blood; Sexual contact; Vertical transmission | Acute hepatitis; Chronic hepatitis; Cirrhosis; Hepatocellular carcinoma | Unprotected sex; IVDU; Healthcare workers; Vertical transmission | **Management:** Antivirals (tenofovir, entecavir). **Prevention:** HBV vaccine; Safe sex; Screen blood; Universal precautions |
| **Parvoviridae** | Parvovirus B19 | ssDNA, linear | Non-enveloped | Respiratory droplets; Vertical transmission; Blood | Erythema infectiosum (fifth disease); Aplastic crisis (sickle cell); Hydrops fetalis | Children; Pregnancy; Sickle cell disease; Immunosuppression | **Management:** Supportive care; IVIG for severe cases. **Prevention:** Hand hygiene; Avoid exposure in pregnancy |

### RNA VIRUSES

| Family | Virus | Genome | Envelope | Transmission | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|--------|-------|--------|----------|--------------|------------------------|-------------|----------------------------------|
| **Picornaviridae** | Poliovirus | (+)ssRNA | Non-enveloped | Fecal-oral | Poliomyelitis; Aseptic meningitis; Flaccid paralysis | Unvaccinated; Endemic areas | **Management:** Supportive care. **Prevention:** Polio vaccine (OPV/IPV) |
| **Picornaviridae** | Coxsackievirus | (+)ssRNA | Non-enveloped | Fecal-oral; Respiratory | Hand-foot-mouth disease; Herpangina; Myocarditis; Aseptic meningitis | Children; Crowding | **Management:** Supportive care. **Prevention:** Hand hygiene |
| **Picornaviridae** | Echovirus | (+)ssRNA | Non-enveloped | Fecal-oral; Respiratory | Aseptic meningitis; Rash; Respiratory illness | Children; Crowding | **Management:** Supportive care. **Prevention:** Hand hygiene |
| **Picornaviridae** | Enterovirus (EV-A71, EV-D68) | (+)ssRNA | Non-enveloped | Fecal-oral; Respiratory | Hand-foot-mouth disease; Encephalitis; Acute flaccid myelitis | Children; Asia-Pacific region | **Management:** Supportive care. **Prevention:** Hand hygiene |
| **Picornaviridae** | Rhinovirus | (+)ssRNA | Non-enveloped | Respiratory droplets; Fomites | Common cold | Crowding; Winter months; Daycare | **Management:** Supportive care. **Prevention:** Hand hygiene |
| **Picornaviridae** | Hepatitis A Virus (HAV) | (+)ssRNA | Non-enveloped | Fecal-oral; Contaminated food/water | Acute hepatitis; No chronic infection | Poor sanitation; Travel to endemic areas; Shellfish consumption | **Management:** Supportive care. **Prevention:** HAV vaccine; Hand hygiene; Safe food/water |
| **Caliciviridae** | Norovirus | (+)ssRNA | Non-enveloped | Fecal-oral; Contaminated food/water; Fomites | Gastroenteritis; Vomiting; Diarrhea | Cruises; Healthcare facilities; Contaminated food | **Management:** Supportive care; Rehydration. **Prevention:** Hand hygiene with soap (resistant to alcohol); Food safety |
| **Caliciviridae** | Sapovirus | (+)ssRNA | Non-enveloped | Fecal-oral | Gastroenteritis | Children; Contaminated food/water | **Management:** Supportive care. **Prevention:** Hand hygiene; Food safety |
| **Reoviridae** | Rotavirus | dsRNA, segmented | Non-enveloped | Fecal-oral | Gastroenteritis; Severe diarrhea in children | Children <5 years; Daycare; Winter months | **Management:** Supportive care; Rehydration. **Prevention:** Rotavirus vaccine; Hand hygiene |
| **Flaviviridae** | Dengue Virus (DENV-1 to 4) | (+)ssRNA | Enveloped | Aedes mosquito bite | Dengue fever; Dengue hemorrhagic fever; Dengue shock syndrome | Tropical/subtropical regions; Urban areas; Aedes mosquito exposure | **Management:** Supportive care; Fluid management. **Prevention:** Mosquito control; Dengue vaccine (in some regions) |
| **Flaviviridae** | Zika Virus | (+)ssRNA | Enveloped | Aedes mosquito bite; Sexual contact; Vertical transmission | Mild febrile illness; Microcephaly (congenital); Guillain-Barré syndrome | Pregnancy; Tropical regions; Aedes mosquito exposure | **Management:** Supportive care. **Prevention:** Mosquito control; Avoid travel to endemic areas during pregnancy |
| **Flaviviridae** | Yellow Fever Virus | (+)ssRNA | Enveloped | Aedes/Haemagogus mosquito bite | Yellow fever; Hepatitis; Hemorrhagic fever; Jaundice | Tropical Africa/South America; Unvaccinated travelers | **Management:** Supportive care. **Prevention:** Yellow fever vaccine; Mosquito control |
| **Flaviviridae** | Japanese Encephalitis Virus | (+)ssRNA | Enveloped | Culex mosquito bite | Japanese encephalitis; Meningitis; Movement disorders; Seizures | Rural Asia; Rice fields; Pig farming areas | **Management:** Supportive care. **Prevention:** Japanese encephalitis vaccine; Mosquito control |
| **Flaviviridae** | West Nile Virus | (+)ssRNA | Enveloped | Culex mosquito bite | Mild febrile illness; West Nile neuroinvasive disease (meningitis, encephalitis) | Elderly; Immunosuppression; Mosquito exposure | **Management:** Supportive care. **Prevention:** Mosquito control; Repellents |
| **Flaviviridae** | Hepatitis C Virus (HCV) | (+)ssRNA | Enveloped | Blood; IVDU; Sexual contact (rare) | Acute hepatitis; Chronic hepatitis (70-80%); Cirrhosis; Hepatocellular carcinoma | IVDU; Blood transfusion (pre-1992); Healthcare workers | **Management:** Direct-acting antivirals (DAAs). **Prevention:** Screen blood; Harm reduction; Universal precautions |
| **Togaviridae** | Rubella Virus | (+)ssRNA | Enveloped | Respiratory droplets; Vertical transmission | Rubella (German measles); Congenital rubella syndrome (deafness, cataracts, heart defects) | Unvaccinated; Pregnancy | **Management:** Supportive care. **Prevention:** MMR vaccine |
| **Togaviridae** | Chikungunya Virus | (+)ssRNA | Enveloped | Aedes mosquito bite | Chikungunya fever; Severe arthralgia; Rash | Tropical regions; Aedes mosquito exposure | **Management:** Supportive care; NSAIDs. **Prevention:** Mosquito control; Repellents |
| **Coronaviridae** | SARS-CoV-2 | (+)ssRNA | Enveloped | Respiratory droplets; Aerosols; Fomites | COVID-19; Pneumonia; ARDS; Long COVID | Elderly; Comorbidities (diabetes, obesity); Unvaccinated | **Management:** Supportive care; Antivirals; Monoclonals. **Prevention:** COVID-19 vaccine; Masks; Social distancing |
| **Coronaviridae** | SARS-CoV | (+)ssRNA | Enveloped | Respiratory droplets; Fomites | SARS; Severe pneumonia; ARDS | Healthcare workers; Close contact; 2003 outbreak | **Management:** Supportive care. **Prevention:** Infection control; Isolation |
| **Coronaviridae** | MERS-CoV | (+)ssRNA | Enveloped | Camel contact; Respiratory droplets | MERS; Severe pneumonia; Renal failure | Middle East; Camel exposure; Healthcare workers | **Management:** Supportive care. **Prevention:** Avoid camel contact; Infection control |
| **Coronaviridae** | Human Coronavirus (229E, OC43, NL63, HKU1) | (+)ssRNA | Enveloped | Respiratory droplets | Common cold; Mild upper respiratory infection | Crowding; Winter months | **Management:** Supportive care. **Prevention:** Hand hygiene |
| **Orthomyxoviridae** | Influenza A, B, C | (-)ssRNA, segmented | Enveloped | Respiratory droplets; Aerosols | Influenza; Pneumonia; Myositis; Encephalitis | Elderly; Young children; Pregnancy; Chronic diseases; Unvaccinated | **Management:** Oseltamivir; Zanamivir. **Prevention:** Influenza vaccine; Hand hygiene; Respiratory etiquette |
| **Paramyxoviridae** | Measles Virus | (-)ssRNA | Enveloped | Respiratory droplets; Highly contagious | Measles; Pneumonia; Encephalitis; Subacute sclerosing panencephalitis (SSPE) | Unvaccinated; Crowding; Immunosuppression | **Management:** Supportive care; Vitamin A. **Prevention:** MMR vaccine |
| **Paramyxoviridae** | Mumps Virus | (-)ssRNA | Enveloped | Respiratory droplets; Saliva | Mumps; Parotitis; Orchitis; Meningitis; Pancreatitis | Unvaccinated; Adolescents/young adults | **Management:** Supportive care. **Prevention:** MMR vaccine |
| **Paramyxoviridae** | Respiratory Syncytial Virus (RSV) | (-)ssRNA | Enveloped | Respiratory droplets; Fomites | Bronchiolitis; Pneumonia in infants | Infants <2 years; Premature infants; Chronic lung disease; Winter months | **Management:** Supportive care; Oxygen; Palivizumab (prophylaxis). **Prevention:** Hand hygiene; RSV vaccine (in development) |
| **Paramyxoviridae** | Parainfluenza Virus (1-4) | (-)ssRNA | Enveloped | Respiratory droplets | Croup; Bronchiolitis; Pneumonia | Children; Autumn/winter | **Management:** Supportive care. **Prevention:** Hand hygiene |
| **Paramyxoviridae** | Nipah Virus | (-)ssRNA | Enveloped | Fruit bat exposure; Pig contact; Person-to-person | Nipah virus encephalitis; Respiratory illness; High mortality | Southeast Asia; Fruit bat/pig exposure; Healthcare workers | **Management:** Supportive care. **Prevention:** Avoid fruit bat exposure; Infection control |
| **Rhabdoviridae** | Rabies Virus | (-)ssRNA | Enveloped | Animal bite (dog, bat, etc.); Saliva | Rabies; Encephalitis; Hydrophobia; Paralysis; 100% fatal once symptomatic | Dog/bat bites; Travel to endemic areas | **Management:** Post-exposure prophylaxis (vaccine + HRIG). **Prevention:** Pre-exposure vaccine (high-risk); Animal vaccination; Avoid wild animals |
| **Filoviridae** | Ebola Virus | (-)ssRNA | Enveloped | Direct contact with body fluids; Bushmeat | Ebola hemorrhagic fever; High mortality | West Africa; Healthcare workers; Handling infected individuals/animals | **Management:** Supportive care; Monoclonal antibodies. **Prevention:** Ebola vaccine; Infection control; Avoid bushmeat |
| **Filoviridae** | Marburg Virus | (-)ssRNA | Enveloped | Bat exposure; Direct contact with body fluids | Marburg hemorrhagic fever; High mortality | Africa; Bat exposure; Healthcare workers | **Management:** Supportive care. **Prevention:** Infection control; Avoid bat exposure |
| **Arenaviridae** | Lassa Virus | (-)ssRNA, segmented | Enveloped | Rodent excreta; Person-to-person | Lassa fever; Hemorrhagic fever | West Africa; Rodent exposure; Healthcare workers | **Management:** Ribavirin. **Prevention:** Rodent control; Infection control |
| **Hantaviridae** | Hantavirus | (-)ssRNA, segmented | Enveloped | Inhalation of rodent excreta | Hantavirus pulmonary syndrome (HPS); Hemorrhagic fever with renal syndrome (HFRS) | Rural areas; Rodent exposure; Occupational (farming) | **Management:** Supportive care. **Prevention:** Rodent control; Avoid rodent-infested areas |
| **Retroviridae** | Human Immunodeficiency Virus (HIV-1, HIV-2) | ssRNA (2 copies) with RT | Enveloped | Sexual contact; Blood; Vertical transmission; IVDU | AIDS; Opportunistic infections; Malignancies; Immunodeficiency | Unprotected sex; IVDU; Vertical transmission; Multiple sexual partners | **Management:** HAART (antiretroviral therapy). **Prevention:** Safe sex; PrEP; Screen blood; PMTCT; Harm reduction |
| **Retroviridae** | Human T-lymphotropic Virus (HTLV-1, HTLV-2) | ssRNA with RT | Enveloped | Sexual contact; Blood; Vertical transmission (breastfeeding) | Adult T-cell leukemia/lymphoma (ATL); HTLV-associated myelopathy (HAM/TSP) | Endemic areas (Japan, Caribbean); IVDU; Breastfeeding | **Management:** Chemotherapy for ATL; Supportive for HAM. **Prevention:** Screen blood; Avoid breastfeeding if infected |
| **Hepeviridae** | Hepatitis E Virus (HEV) | (+)ssRNA | Non-enveloped | Fecal-oral; Contaminated water | Acute hepatitis; Fulminant hepatitis in pregnancy | Pregnancy; Endemic areas (South Asia); Contaminated water | **Management:** Supportive care; Ribavirin in severe cases. **Prevention:** Safe water; Sanitation |
| **Astroviridae** | Astrovirus | (+)ssRNA | Non-enveloped | Fecal-oral | Gastroenteritis in children | Children; Elderly; Immunosuppression | **Management:** Supportive care. **Prevention:** Hand hygiene |

---

## MEDICALLY IMPORTANT PROTOZOA

### INTESTINAL PROTOZOA (DYSENTERY - BLOODY DIARRHEA)

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Amoeba** | *Entamoeba histolytica* | Microscopy: Trophozoites with ingested RBCs; 4-nucleated cysts; Antigen detection; PCR | Large intestine (colon) | Fecal-oral; Contaminated food/water; Person-to-person | Cysteine proteinase; Amoebapore; Lectin (adherence); Tissue invasion | Amoebic dysentery; Bloody diarrhea; Amoebic liver abscess (ALA); Colonic ulcers; Amoeboma; Peritonitis | Poor sanitation; Crowded living; Male homosexuals; Institutionalized groups | **Management:** Metronidazole/tinidazole + intraluminal agent (paromomycin, iodoquinol). **Prevention:** Boil water; Hand hygiene; Safe food handling; Proper sewage disposal |
| **Ciliate** | *Balantidium coli* | Microscopy: Large binucleated trophozoite (50-100 μm) with cilia; Cysts | Large intestine (colon) | Fecal-oral; Contaminated water; Pig reservoir | Hyaluronidase; Proteolytic enzymes; Tissue invasion | Balantidiasis; Dysentery; Bloody diarrhea; Colonic ulcers; Peritonitis (rare); Urogenital invasion | Pig-rearing communities; Farmers; Poor sanitation | **Management:** Tetracycline/metronidazole/iodoquinol. **Prevention:** Good sanitation; Boil water; Restrict pigs from water supplies |

### INTESTINAL PROTOZOA (MALABSORPTION - WATERY DIARRHEA)

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Flagellate** | *Giardia lamblia (G. intestinalis/duodenalis)* | Microscopy: Trophozoites (pear-shaped with "face"); 4-nucleated cysts; DFA; PCR | Small intestine (duodenum) | Fecal-oral; Contaminated water; Person-to-person | Ventral sucking disc; Cysteine proteases; Disrupts brush border | Giardiasis; Watery diarrhea (foul-smelling); Malabsorption; Steatorrhea; Flatulence; Weight loss; Failure to thrive | Children in daycare; Travelers; Immunocompromised; Contaminated water (beavers = "beaver fever") | **Management:** Metronidazole/tinidazole/nitazoxanide. **Prevention:** Boil/filter water; Hand hygiene; Proper sewage disposal |
| **Apicomplexa** | *Cryptosporidium parvum/hominis* | Microscopy: Acid-fast oocysts (4-6 μm); Autofluorescence under UV; Antigen detection; PCR | Small intestine (jejunum) | Fecal-oral; Contaminated water; Animal contact; Oocysts infectious immediately | Attachment to enterocytes; Intracellular invasion; Immune evasion | Cryptosporidiosis; Watery diarrhea (profuse in immunocompromised); Self-limited in immunocompetent; Malabsorption; Weight loss | HIV/AIDS; Children <5 years; Immunosuppression; Contaminated water (chlorine-resistant) | **Management:** Nitazoxanide; HAART (HIV); Supportive care. **Prevention:** Boil/filter water; Hand hygiene; HAART for HIV |
| **Apicomplexa** | *Cystoisospora (Isospora) belli* | Microscopy: Acid-fast oocysts (large, 20-30 μm); Immature oocysts in stool | Small intestine | Fecal-oral; Contaminated food/water | Enterocyte invasion; Intracellular replication | Cystoisosporiasis; Watery diarrhea; Malabsorption; Steatorrhea; Eosinophilia; Weight loss | HIV/AIDS; Immunosuppression; Tropical regions | **Management:** TMP-SMX (co-trimoxazole); HAART (HIV). **Prevention:** Safe food/water; HAART; Hand hygiene |
| **Apicomplexa** | *Cyclospora cayetanensis* | Microscopy: Acid-fast oocysts (8-10 μm); Autofluorescence under UV; PCR | Small intestine (duodenum, jejunum) | Fecal-oral; Contaminated produce (berries, herbs); Water | Enterocyte invasion; Oocysts need time to sporulate (not immediately infectious) | Cyclosporiasis; Watery diarrhea; Fatigue; Anorexia; Weight loss; Prolonged in immunocompromised | Endemic regions (Central/South America, Nepal); Imported produce; Immunosuppression | **Management:** TMP-SMX; Nitazoxanide. **Prevention:** Wash produce; Safe water; Food safety |
| **Microsporidia** | *Enterocytozoon bieneusi*, *Encephalitozoon intestinalis* | Microscopy: Gram-chromotrope stain (spores 1-3 μm); PCR; TEM (gold standard) | Small intestine (also systemic for *E. intestinalis*) | Fecal-oral; Inhalation; Contaminated water | Obligate intracellular; Polar tubule injection | Microsporidiosis; Watery diarrhea; Wasting syndrome; Cholangitis; Disseminated disease (*E. intestinalis*) | HIV/AIDS; Immunosuppression; Organ transplantation | **Management:** Albendazole (*E. intestinalis*); Fumagillin (*E. bieneusi*); HAART. **Prevention:** Safe water; HAART; Hand hygiene |
| **Uncertain** | *Blastocystis* species | Microscopy: Vacuolar forms in stool; PCR | Large intestine | Fecal-oral; Contaminated food/water | Uncertain pathogenicity (controversial) | Usually asymptomatic; Possibly watery diarrhea; Abdominal pain | Developing countries; Poor sanitation; Controversial if truly pathogenic | **Management:** Metronidazole/nitazoxanide (if symptomatic). **Prevention:** Safe food/water; Hand hygiene |

### UROGENITAL PROTOZOA

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Flagellate** | *Trichomonas vaginalis* | Microscopy: Motile trophozoites with 4 flagella; Wet mount; Culture; Antigen detection; PCR | Vagina, urethra, prostate | Sexual contact; Rarely fomites | Adherence; Cytotoxic proteases; Hemolysins; Pseudocyst formation | Trichomoniasis; Foul-smelling vaginal discharge; Vaginal itching; Dysuria; Strawberry cervix; Often asymptomatic in males; Urethritis; Prostatitis | Multiple sexual partners; Unprotected sex; STI | **Management:** Metronidazole/tinidazole; Treat sexual partners. **Prevention:** Condoms; Limit sexual partners; Screen |

### BLOOD AND TISSUE PROTOZOA (HEMOFLAGELLATES)

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Flagellate** | *Trypanosoma brucei gambiense* | Microscopy: Trypomastigotes in blood/lymph/CSF; CATT; PCR | Blood, lymph, CSF | Tsetse fly (*Glossina*) bite | Antigenic variation (VSG); Immune evasion | African trypanosomiasis (sleeping sickness); Chronic form (years); Hemolymphatic stage: Fever, lymphadenopathy (Winterbottom's sign); Encephalitic stage: CNS involvement, altered sleep, coma, death | West/Central Africa; Tsetse fly exposure; Anthroponotic | **Management:** Early: Pentamidine; Late (CNS): NECT (nifurtimox-eflornithine). **Prevention:** Tsetse fly control; Screening; Early treatment |
| **Flagellate** | *Trypanosoma brucei rhodesiense* | Microscopy: Trypomastigotes in blood/lymph/CSF; PCR | Blood, lymph, CSF | Tsetse fly bite | Antigenic variation; Immune evasion | African trypanosomiasis; Acute form (weeks-months); More severe; High mortality | East/Southern Africa; Tsetse fly exposure; Zoonotic (difficult reservoir control) | **Management:** Early: Suramin; Late (CNS): Melarsoprol. **Prevention:** Tsetse fly control; Avoid wild animal areas |
| **Flagellate** | *Trypanosoma cruzi* | Microscopy: Trypomastigotes in blood; Amastigotes in tissue; Serology; PCR | Blood, heart, GI smooth muscle | Reduviid/kissing bug bite; Blood transfusion; Vertical transmission | Intracellular survival; Immune evasion; Tissue destruction | Chagas disease; Acute: Chagoma, Romana's sign, fever; Chronic: Cardiomyopathy, megaesophagus, megacolon | Central/South America; Rural areas; Poor housing; Blood transfusion | **Management:** Acute: Benznidazole/nifurtimox; Chronic: Supportive (limited efficacy). **Prevention:** Insecticide; Improved housing; Screen blood |
| **Flagellate** | *Leishmania donovani* | Microscopy: Amastigotes in macrophages; Culture (promastigotes); PCR | Reticuloendothelial system (liver, spleen, bone marrow) | Sandfly (*Phlebotomus*) bite | Intracellular survival in macrophages; Immune modulation | Visceral leishmaniasis (kala-azar); Fever, hepatosplenomegaly, anemia, weight loss; Post-kala-azar dermal leishmaniasis | Indian subcontinent; East Africa; Sandfly exposure; Immunosuppression; HIV | **Management:** Liposomal amphotericin B; Miltefosine. **Prevention:** Sandfly control; Insect repellent; Treat reservoir dogs |
| **Flagellate** | *Leishmania tropica* | Microscopy: Amastigotes in skin; Culture; PCR | Skin | Sandfly bite | Intracellular survival; Granuloma formation | Cutaneous leishmaniasis (oriental sore); Skin ulcers | Middle East; Mediterranean; Sandfly exposure | **Management:** Local treatment; Pentavalent antimonials. **Prevention:** Sandfly control; Insect repellent |
| **Flagellate** | *Leishmania braziliensis* | Microscopy: Amastigotes; Culture; PCR | Skin, mucosa | Sandfly bite | Intracellular survival; Mucosal spread | Mucocutaneous leishmaniasis; Destructive nasopharyngeal lesions | Central/South America; Sandfly exposure | **Management:** Pentavalent antimonials; Amphotericin B. **Prevention:** Sandfly control; Insect repellent |

### BLOOD AND TISSUE PROTOZOA (APICOMPLEXA)

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Apicomplexa** | *Plasmodium falciparum* | Microscopy: Ring forms, gametocytes (banana-shaped) in blood smear; RDT; PCR | RBCs (no exoerythrocytic stage relapse) | Anopheles mosquito bite | Cytoadherence; Rosetting; Sequestration; Hemozoin | Malaria; Severe malaria; Cerebral malaria; High parasitemia; Blackwater fever; Anemia; Hypoglycemia | Sub-Saharan Africa; Non-immune travelers; Pregnancy; Children | **Management:** Artemisinin-based combination therapy (ACT). **Prevention:** Mosquito nets; Chemoprophylaxis; Indoor residual spraying |
| **Apicomplexa** | *Plasmodium vivax* | Microscopy: Ring forms, amoeboid trophozoites, Schüffner's dots; Enlarged RBCs; RDT; PCR | RBCs, liver (hypnozoites) | Anopheles mosquito bite | Hypnozoites (relapse); Duffy antigen binding | Malaria; Relapsing malaria; Tertian fever (48 hr); Anemia; Splenomegaly | Asia, Latin America; Relapse months-years after primary infection | **Management:** ACT + Primaquine (for hypnozoites). **Prevention:** Mosquito nets; Chemoprophylaxis; G6PD testing before primaquine |
| **Apicomplexa** | *Plasmodium ovale* | Microscopy: Schüffner's dots; Enlarged RBCs; Oval-shaped; RDT; PCR | RBCs, liver (hypnozoites) | Anopheles mosquito bite | Hypnozoites (relapse) | Malaria; Relapsing malaria; Tertian fever; Milder than vivax | West Africa; Rare outside Africa | **Management:** ACT + Primaquine. **Prevention:** Mosquito nets; Chemoprophylaxis |
| **Apicomplexa** | *Plasmodium malariae* | Microscopy: Band forms, rosette schizonts; Normal RBC size; RDT; PCR | RBCs (long-term infection, no hypnozoites) | Anopheles mosquito bite | Persistent low-level parasitemia | Malaria; Quartan fever (72 hr); Nephrotic syndrome | Worldwide (less common); Can persist for decades | **Management:** ACT or chloroquine. **Prevention:** Mosquito nets; Chemoprophylaxis |
| **Apicomplexa** | *Plasmodium knowlesi* | Microscopy: All stages present; Resembles P. malariae/falciparum; PCR essential | RBCs | Anopheles mosquito bite; Zoonotic (macaques) | Rapid replication (24 hr cycle); High parasitemia | Malaria; Severe malaria possible; Quotidian fever (24 hr) | Southeast Asia (Malaysia, Borneo); Forest exposure; Macaque reservoir | **Management:** ACT; IV artesunate for severe. **Prevention:** Mosquito nets; Avoid forest areas at dusk/dawn |
| **Apicomplexa** | *Babesia microti* | Microscopy: Maltese cross (tetrad); Ring forms (no pigment); PCR | RBCs | Ixodid tick (*Ixodes*) bite; Blood transfusion | Invasion of RBCs; Hemolysis; Immune evasion | Babesiosis; Hemolytic anemia; Fever; Flu-like; Severe in asplenic/immunocompromised | Northeast/Midwest USA; Tick exposure; Asplenia; Immunosuppression; Elderly | **Management:** Atovaquone + azithromycin; Exchange transfusion if severe. **Prevention:** Tick avoidance; Protective clothing; Defer blood donation |
| **Apicomplexa** | *Toxoplasma gondii* | Serology (IgM/IgG); PCR; Microscopy: Tachyzoites, bradyzoites in tissue cysts | CNS, eye, muscle, lymph nodes | Ingestion of oocysts (cat feces); Undercooked meat (tissue cysts); Vertical transmission | Intracellular survival; Tissue cyst formation; Immune evasion | Toxoplasmosis; Usually asymptomatic; Lymphadenitis; Congenital: TORCH syndrome (chorioretinitis, hydrocephalus, calcifications); Encephalitis (HIV); Chorioretinitis | Immunocompromised (HIV, transplant); Pregnancy; Cat ownership; Undercooked meat | **Management:** Pyrimethamine + sulfadiazine + folinic acid; Spiramycin (pregnancy). **Prevention:** Cook meat thoroughly; Avoid cat litter; Hand hygiene; Screen in pregnancy |

### FREE-LIVING AMOEBAE

| Type | Name | Test/Identification | Colonisation Site | Transmission | Virulence Factor/Pathogenesis | Clinical Manifestation | Risk Factor | Management, Prevention & Control |
|------|------|---------------------|-------------------|--------------|-------------------------------|------------------------|-------------|----------------------------------|
| **Amoeba** | *Naegleria fowleri* | Microscopy: Trophozoites in CSF; Culture at 37°C; PCR | CNS (meninges, brain) | Swimming in warm freshwater; Nasal insufflation | Cytopathic effect; Phagocytosis; Contact-dependent cytolysis | Primary amoebic meningoencephalitis (PAM); Fulminant meningitis; Headache, fever, altered mental status; Death in 3-7 days; >95% mortality | Swimming in warm freshwater (lakes, hot springs); Nasal exposure | **Management:** Amphotericin B + miltefosine (limited success). **Prevention:** Avoid warm freshwater; Don't submerge head; Nose clips |
| **Amoeba** | *Acanthamoeba* species | Microscopy: Trophozoites/cysts in tissue; Culture; PCR | CNS, eye (cornea) | Contact lens contamination; Soil/water exposure | Cytopathic effect; Protease; Immune evasion | Granulomatous amoebic encephalitis (GAE); Subacute/chronic; Amoebic keratitis; Corneal ulcer, pain, vision loss | Immunocompromised (GAE); Contact lens wearers (keratitis); Soil/water exposure | **Management:** GAE: Pentamidine + azoles (poor prognosis); Keratitis: Polyhexamethylene biguanide + propamidine. **Prevention:** Proper contact lens hygiene; Avoid tap water for lenses |

---

**Abbreviations:**
- dsDNA = double-stranded DNA
- ssDNA = single-stranded DNA
- dsRNA = double-stranded RNA
- ssRNA = single-stranded RNA
- (+)ssRNA = positive-sense single-stranded RNA
- (-)ssRNA = negative-sense single-stranded RNA
- RT = reverse transcriptase
- GMS = Grocott-Gomori methenamine silver stain
- PAS = Periodic acid-Schiff stain
- KOH = Potassium hydroxide
- SDA = Sabouraud dextrose agar
- DFA = Direct fluorescent antibody
- PCR = Polymerase chain reaction
- MALDI-TOF = Matrix-assisted laser desorption ionization-time of flight
- TMP-SMX = Trimethoprim-sulfamethoxazole
- HAART = Highly active antiretroviral therapy
- CSF = Cerebrospinal fluid
- CNS = Central nervous system
- GI = Gastrointestinal
- RBC = Red blood cell
- STI = Sexually transmitted infection
- IVDU = Intravenous drug use
- HIV = Human immunodeficiency virus
- AIDS = Acquired immunodeficiency syndrome
- ARDS = Acute respiratory distress syndrome
- ICU = Intensive care unit
- ACT = Artemisinin-based combination therapy
- RDT = Rapid diagnostic test
- G6PD = Glucose-6-phosphate dehydrogenase
- TORCH = Toxoplasmosis, Other, Rubella, Cytomegalovirus, Herpes
